Comment Letters

  • RE: Washington State Health Care Authority Health Technology Assessment draft findings and decision on Functional Neuroimaging for Primary Degenerative Dementia or Mild Cognitive Impairment Dear Director Teeter: The Medical Imaging & Technology Alliance (MITA) is pleased to submit a comment on the Washington State Health Care Authority (HCA) Health Technology Assessment (HTA) Draft Findings and Read More

  • RE: Washington State Health Care Authority Health Technology Assessment draft decision on Appropriate Imaging for Breast Cancer Screening in Special Populations. Dear Director Teeter: The Medical Imaging & Technology Alliance (MITA) is pleased to submit comments on the Washington State Health Care Authority (HCA) Health Technology Assessment (HTA) Draft decision on Appropriate Imaging for Breast Read More

  • RE: Requests for Scientific Information: Imaging for Pretreatment Staging of Small Cell Lung Cancer Dear Dr. Kronick: The Medical Imaging & Technology Alliance (MITA) is pleased to submit comments on the Agency for Healthcare Research and Quality (AHRQ) Requests for Scientific Information: Imaging for Pretreatment Staging of Small Cell Lung Cancer (“Requests for Scientific Information”).1 Read More

  • MITA submitted comments to CMS on the Proposed Decision Memorandum on Screening for Lung Cancer with Low Dose Computed Tomography (LDCT).

  • The Medical Imaging & Technology Alliance (MITA) is pleased to submit comments on the Agency for Healthcare Research and Quality (AHRQ) Draft Key Questions on Imaging for Pretreatment Staging of Small Cell Lung Carcinoma (“Draft Key Questions”).

  • Dear Administrator Tavenner: The Medical Imaging & Technology Alliance (MITA) appreciates this opportunity to submit comments on the Centers for Medicare and Medicaid Services’ (CMS) proposed rule regarding the hospital outpatient prospective payment system (OPPS) and calendar year (CY 2015) rates, published in the Federal Register on July 14, 2014 (Proposed Rule). As the leading Read More

  • Dear Administrator Tavenner: The Medical Imaging & Technology Alliance (MITA) is pleased to submit comments on the Centers for Medicare and Medicaid Services’ (CMS’) proposed rule regarding the payment policies under the physician fee schedule (PFS) for calendar year 2015 (CY 2015), published in the Federal Register on July 11, 2014 (Proposed Rule). As the Read More

  • Dear Senators Wyden & Grassley, Thank you for your open letter highlighting the need for Congressional consideration of health care data transparency opportunities that have the potential to improve health care quality and value for patients and taxpayers. On behalf of the medical imaging, radiation therapy, and radiopharmaceutical industry, the Medical Imaging & Technology Alliance Read More

  • Dear Administrator Tavenner: We, the undersigned organizations, write to identify certain pressing issues related to implementation of the Physician Payments Sunshine Act (Sunshine Act). As representatives of multiple physician organizations and manufacturers that are impacted by the law, we are committed to the success of the Sunshine Act. Accordingly, we are reaching out to you Read More

  • Dear Director Teeter: The Medical Imaging and Technology Alliance (MITA) is pleased to submit comments on the Washington State Health Care Authority (HCA) Health Technology Assessment (HTA) Draft Key Questions on Appropriate Imaging for Breast Cancer Screening in Special Populations. Every woman has specific screening needs based on a variety of factors including age, family Read More



  • Imaging Forward

    In just 20 years, medical imaging has dramatically improved health outcomes and lowered costs. Imagine what the future holds. Learn More


  • The State of Medical Imaging

    New MITA Infographic highlights the current threats to medical imaging, as well as patient-centered policy proposals. Learn More

  • Navidea

    Why I Joined MITA – Navidea Biopharmaceuticals

    Hear from Thomas Tulip, Executive Vice President and Chief Business Officer of Navidea Biopharmaceuticals, on why his organization joined MITA.

    Learn More